Doppler sonography measurement of portal blood flow velocity after glucagon injection in patients with chronic HCV infection

Silvia Sereno, Fabrizio Toccaceli, Vincenzo Russo, Fabio Iacomi, Enrico Maria Zardi, Vittorio Laghi

Research output: Contribution to journalArticle

Abstract

Doppler sonography measurement of portal flow velocity (PFV) after glucagon injection was performed in 45 patients with chronic hepatitis C virus (HCV) infection. Patients were divided into three groups: group 1 = no or mild liver fibrosis; group 2 = moderate to severe liver fibrosis, and group 3 = liver cirrhosis. All patients were examined using a Doppler ultrasound (US) multipurpose equipment and a convex 3.5-MHz probe, 10 min before (baseline), as well as 5 and 10 min after, IV administration of 1 mg of glucagon chloride. No significant differences were found in mean baseline PFV among group 1 (19.4 ± 2.4 cm/s), group 2 (20.1 ± 3.6 cm/s) and group 3 (17.5 ± 3.7 cm/s). Five minutes after glucagon injection, all three groups showed significantly increased values of mean PFV (25.6 ± 4.8, 23.7 ± 4.0 and 19.5 ± 5.0 cm/s, respectively; p <0.05 vs. baseline). The mean increase of PFV above baseline was significantly higher in group 1 (7.9 ± 3.7 cm/s) than in group 2 (4.5 ± 3.9 cm/s) (p <0.05) or in group 3 (2.7 ± 2.3 cm/s) (p <0.05). A significant inverse correlation was found between individual values of fibrosis score and of individual increase of PFV. In patients with chronic HCV infection, Doppler sonography measurement of PFV after glucagon injection could be useful in assessing the severity of liver histological damage.

Original languageEnglish
Pages (from-to)723-726
Number of pages4
JournalUltrasound in Medicine and Biology
Volume27
Issue number5
DOIs
Publication statusPublished - 2001

Fingerprint

hepatitis
Doppler Ultrasonography
Blood Flow Velocity
viruses
infectious diseases
Chronic Hepatitis C
Virus Diseases
blood flow
Glucagon
Hepacivirus
flow velocity
Liver Cirrhosis
injection
Injections
liver
fibrosis
Chlorides
Fibrosis
Equipment and Supplies
Liver

Keywords

  • Doppler sonography
  • Glucagon
  • HCV infection
  • Portal flow velocity

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Doppler sonography measurement of portal blood flow velocity after glucagon injection in patients with chronic HCV infection. / Sereno, Silvia; Toccaceli, Fabrizio; Russo, Vincenzo; Iacomi, Fabio; Zardi, Enrico Maria; Laghi, Vittorio.

In: Ultrasound in Medicine and Biology, Vol. 27, No. 5, 2001, p. 723-726.

Research output: Contribution to journalArticle

Sereno, Silvia ; Toccaceli, Fabrizio ; Russo, Vincenzo ; Iacomi, Fabio ; Zardi, Enrico Maria ; Laghi, Vittorio. / Doppler sonography measurement of portal blood flow velocity after glucagon injection in patients with chronic HCV infection. In: Ultrasound in Medicine and Biology. 2001 ; Vol. 27, No. 5. pp. 723-726.
@article{69eeeb9a3e6d4274aade6fc080bf0c18,
title = "Doppler sonography measurement of portal blood flow velocity after glucagon injection in patients with chronic HCV infection",
abstract = "Doppler sonography measurement of portal flow velocity (PFV) after glucagon injection was performed in 45 patients with chronic hepatitis C virus (HCV) infection. Patients were divided into three groups: group 1 = no or mild liver fibrosis; group 2 = moderate to severe liver fibrosis, and group 3 = liver cirrhosis. All patients were examined using a Doppler ultrasound (US) multipurpose equipment and a convex 3.5-MHz probe, 10 min before (baseline), as well as 5 and 10 min after, IV administration of 1 mg of glucagon chloride. No significant differences were found in mean baseline PFV among group 1 (19.4 ± 2.4 cm/s), group 2 (20.1 ± 3.6 cm/s) and group 3 (17.5 ± 3.7 cm/s). Five minutes after glucagon injection, all three groups showed significantly increased values of mean PFV (25.6 ± 4.8, 23.7 ± 4.0 and 19.5 ± 5.0 cm/s, respectively; p <0.05 vs. baseline). The mean increase of PFV above baseline was significantly higher in group 1 (7.9 ± 3.7 cm/s) than in group 2 (4.5 ± 3.9 cm/s) (p <0.05) or in group 3 (2.7 ± 2.3 cm/s) (p <0.05). A significant inverse correlation was found between individual values of fibrosis score and of individual increase of PFV. In patients with chronic HCV infection, Doppler sonography measurement of PFV after glucagon injection could be useful in assessing the severity of liver histological damage.",
keywords = "Doppler sonography, Glucagon, HCV infection, Portal flow velocity",
author = "Silvia Sereno and Fabrizio Toccaceli and Vincenzo Russo and Fabio Iacomi and Zardi, {Enrico Maria} and Vittorio Laghi",
year = "2001",
doi = "10.1016/S0301-5629(01)00347-7",
language = "English",
volume = "27",
pages = "723--726",
journal = "Ultrasound in Medicine and Biology",
issn = "0301-5629",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - Doppler sonography measurement of portal blood flow velocity after glucagon injection in patients with chronic HCV infection

AU - Sereno, Silvia

AU - Toccaceli, Fabrizio

AU - Russo, Vincenzo

AU - Iacomi, Fabio

AU - Zardi, Enrico Maria

AU - Laghi, Vittorio

PY - 2001

Y1 - 2001

N2 - Doppler sonography measurement of portal flow velocity (PFV) after glucagon injection was performed in 45 patients with chronic hepatitis C virus (HCV) infection. Patients were divided into three groups: group 1 = no or mild liver fibrosis; group 2 = moderate to severe liver fibrosis, and group 3 = liver cirrhosis. All patients were examined using a Doppler ultrasound (US) multipurpose equipment and a convex 3.5-MHz probe, 10 min before (baseline), as well as 5 and 10 min after, IV administration of 1 mg of glucagon chloride. No significant differences were found in mean baseline PFV among group 1 (19.4 ± 2.4 cm/s), group 2 (20.1 ± 3.6 cm/s) and group 3 (17.5 ± 3.7 cm/s). Five minutes after glucagon injection, all three groups showed significantly increased values of mean PFV (25.6 ± 4.8, 23.7 ± 4.0 and 19.5 ± 5.0 cm/s, respectively; p <0.05 vs. baseline). The mean increase of PFV above baseline was significantly higher in group 1 (7.9 ± 3.7 cm/s) than in group 2 (4.5 ± 3.9 cm/s) (p <0.05) or in group 3 (2.7 ± 2.3 cm/s) (p <0.05). A significant inverse correlation was found between individual values of fibrosis score and of individual increase of PFV. In patients with chronic HCV infection, Doppler sonography measurement of PFV after glucagon injection could be useful in assessing the severity of liver histological damage.

AB - Doppler sonography measurement of portal flow velocity (PFV) after glucagon injection was performed in 45 patients with chronic hepatitis C virus (HCV) infection. Patients were divided into three groups: group 1 = no or mild liver fibrosis; group 2 = moderate to severe liver fibrosis, and group 3 = liver cirrhosis. All patients were examined using a Doppler ultrasound (US) multipurpose equipment and a convex 3.5-MHz probe, 10 min before (baseline), as well as 5 and 10 min after, IV administration of 1 mg of glucagon chloride. No significant differences were found in mean baseline PFV among group 1 (19.4 ± 2.4 cm/s), group 2 (20.1 ± 3.6 cm/s) and group 3 (17.5 ± 3.7 cm/s). Five minutes after glucagon injection, all three groups showed significantly increased values of mean PFV (25.6 ± 4.8, 23.7 ± 4.0 and 19.5 ± 5.0 cm/s, respectively; p <0.05 vs. baseline). The mean increase of PFV above baseline was significantly higher in group 1 (7.9 ± 3.7 cm/s) than in group 2 (4.5 ± 3.9 cm/s) (p <0.05) or in group 3 (2.7 ± 2.3 cm/s) (p <0.05). A significant inverse correlation was found between individual values of fibrosis score and of individual increase of PFV. In patients with chronic HCV infection, Doppler sonography measurement of PFV after glucagon injection could be useful in assessing the severity of liver histological damage.

KW - Doppler sonography

KW - Glucagon

KW - HCV infection

KW - Portal flow velocity

UR - http://www.scopus.com/inward/record.url?scp=0034997905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034997905&partnerID=8YFLogxK

U2 - 10.1016/S0301-5629(01)00347-7

DO - 10.1016/S0301-5629(01)00347-7

M3 - Article

C2 - 11397536

AN - SCOPUS:0034997905

VL - 27

SP - 723

EP - 726

JO - Ultrasound in Medicine and Biology

JF - Ultrasound in Medicine and Biology

SN - 0301-5629

IS - 5

ER -